Study	Reason for exclusion
Aapro 1981	Not a primary study ‐ editorial
Allan 1987	Not a primary study ‐ review
Anderson 1981	Not a primary study ‐ review
Artim 1983	Participants received chemotherapy and radiotherapy
Bateman 1982	Not a primary study ‐ letter
Ben 2006	Not a primary study ‐ review
Biedrzycki 2007	Not a primary study ‐ conference presentation
Broder 1982	Lacks data ‐ abstract of preliminary findings, participant age and characteristics not reported
Carey 1983	Not a primary study ‐ review
Chan 1987	Randomised controlled trial involving children
Chang 1979b	Duplicate of Chang 1979a
Citron 1985	Cross route comparison of intramuscular versus oral cannabinoid
Cocchetto 1981	Not a primary study ‐ review
Colls 1980a	Letter ‐ lacks detail on study methods, participant groups, control intervention and results
Colls 1980b	Did not report data for primary outcome, measurement of nausea and vomiting using a non‐validated measure. No details on participants reported
Cone 1982	Not randomised ‐ single‐arm study
Costa 2007	Not a primary study ‐ review
Cotter 2009	Not a primary study ‐ review
Cronin 1981	Not randomised ‐ single‐arm cross‐over study
Croxford 2003	Not a primary study ‐ review
Cunningham 1985	Control group was cannabinoid monotherapy and not conventional anti‐emetic
Cunningham 1988	Sub‐therapeutic dose of prochlorperazine used
Dalzell 1986	Randomised controlled trial involving children
Darmani 2010	Not a primary study ‐ review
Davis 2007	Not a primary study ‐ review
Davis 2008	Not a primary study ‐ review
Devine 1987	Not randomised ‐ single‐arm cross‐over study
Dodds 1985	Not a primary study ‐ review from thesis
Dow 1984	Not a primary study ‐ letter
Duran 2010	Not an approved formulation of delta‐9‐tetrahydrocannabinol
Ekert 1979	Randomised controlled trial involved children not adults
Ettinger 2007	Not a primary study ‐ clinical practice guidelines
Feyer 2011	Not a primary study ‐ review
Fiore 1984	Not a primary study ‐ review
Fox 1979	Not a primary study ‐ letter
Galal 2009	Not a primary study ‐ review
Gallego 1984	Not a primary study ‐ review
Gerhartz 1983	Not randomised ‐ single‐arm study
Gerra 2010	Not a primary study ‐ review
Goodman 1997	Not a primary study ‐ review
Gorter 1999	Not randomised
Grunberg 1989	Not a primary study ‐ review
Guzman 2003	Not a primary study ‐ review
Heim 1984	Evaluates a non‐approved formulation of delta‐9‐tetrahydrocannabinol
Herrstedt 1998	Not a primary study ‐ review
Herrstedt 2008	Not a primary study ‐ review
Higi 1982	Pilot study
Hiller 1984	Not a primary study ‐ review
Hutcheon 1983	Evaluates a non‐approved formulation of delta‐9‐tetrahydrocannabinol
Jordan 2007	Not a primary study ‐ review
Jordan 2011	Not a primary study ‐ review guideline
Kearsley 1985	Not a primary study ‐ review
Kenny 1982	Non‐randomised single‐arm study
Kluin‐Nelemans 1981a	Duplicate to included
Kluin‐Nelemans 1981b	Not randomised. Abstract with scant details of methods reported
Krasnow 1991	Not a primary study ‐ review
Kreutz 2007	Not a primary study ‐ review
Lane 1989	Duplicate Lane 1991
Lane 1990	Duplicate data. Single‐centre study included in Lane 1991
Laszlo 1982	Not a primary study ‐ review
Levitt 1981	Evaluates ophthalmological outcomes. Nausea and vomiting not evaluated
Levitt 1984	Cross‐route comparison of oral versus smoked cannabis
Lohr 2008	Not a primary study ‐ review
Long 1982	Preliminary data presented
Machado 2008	Not a primary study ‐ systematic review and meta‐analysis
Mechoulam 1978	Not a primary study ‐ drug development
Mechoulam 1999	Not a primary study ‐ review
Mechoulam 2001	Not a primary study ‐ review
Meiri 2007	Not acute nausea and vomiting but evaluating delayed nausea and vomiting
Murakami 1986	Not a primary study ‐ review
Musty 2001	Not a primary study ‐ review
Nagy 1978	Scanty data in an abstract ‐ no extractable data
Navari 2009a	Not a primary study ‐ review
Navari 2009b	Not a primary study ‐ review
Niederle 1986	Evaluates a non‐eligible anti‐emetic (alizapride)
Niiranen 1987	Control group was cannabinoid monotherapy and not conventional anti‐emetic
Nyman 1982	Not a primary study ‐ review
Orr 1980	Duplicate of Orr 1981
Penta 1981	Not a primary study ‐ review
Perwitasari 2011	Not a primary study ‐ review
Phillips 2010	Not a primary study ‐ review
Plasse 1991	Not a primary study ‐ expert opinion
Porta 2002	Not a primary study ‐ review
Poster 1981	Not a primary study ‐ review
Reynolds 2002	Not a primary study ‐ letter
Sallan 1975b	Duplicate study of Sallan 1975a
Sallan 1980	Participants aged 9‐70 years; number or percent of children included not reported
Schuette 1985	Duplicate study reported in Niederle 1986
Sheidler 1984	Evaluates a non‐approved formulation of delta‐9‐tetrahydrocannabinol
Slatkin 2007	Not a primary study ‐ review
Smith 2007	Not a primary study ‐ review
Stambaugh 1982	Cross‐route comparison of intramuscular versus oral cannabinoid
Stambaugh 1984	Evaluates a non‐approved formulation of delta‐9‐tetrahydrocannabinol
Steele 1979	Duplicate study reported in Steele 1980
Stewart 1990	Not a primary study ‐ review
Stuart 1982	Not randomised ‐ single‐arm study
Stuart‐Harris 1983	Not randomised
Sweet 1980	Not a primary study ‐ letter
Toth 2008	Not a primary study ‐ review
Tramer 2001	Not a primary study ‐ review
Ungerleider 1985	Sub‐group analysis of study reported in Ungerleider 1982
Venner 1986	Preliminary results ‐ ongoing study
Vincent 1983	Not a primary study ‐ review
Voth 1997	Not a primary study ‐ review
Wang 2008	Not a primary study ‐ review
Ward 1985	Not a primary study ‐ drug evaluation
Ware 2008	Not a primary study ‐ review
Zuardi 2008	Not a primary study ‐ review